TrialEuropean journal of heart failure2020

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.

Adriaan A Voors et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.